This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > ALXN 1210 for Paroxysmal Nocturnal Haemoglobinuria – First Line

< Back

ALXN 1210 for Paroxysmal Nocturnal Haemoglobinuria – First Line


Cancer and Palliative Care

December 2017

ALXN1210 is an antibody under development that prevents the destruction of red blood cells (RBCs). The drug is administered by intravenous injection that requires fewer dosing regimen compared to current treatment option. If ALXN1210 is licensed for use in the UK, it could represent an additional treatment option for patients with paroxysmal nocturnal haemoglobinuria.


Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

ALXN-1210 for Paroxysmal Nocturnal Haemoglobinuria


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts